Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 127

1.

Regulation of cisplatin-resistant head and neck squamous cell carcinoma by the SRC/ETS-1 signaling pathway.

Yang Z, Liao J, Carter-Cooper BA, Lapidus RG, Cullen KJ, Dan H.

BMC Cancer. 2019 May 22;19(1):485. doi: 10.1186/s12885-019-5664-7.

2.

The American Cancer Society 2035 challenge goal on cancer mortality reduction.

Ma J, Jemal A, Fedewa SA, Islami F, Lichtenfeld JL, Wender RC, Cullen KJ, Brawley OW.

CA Cancer J Clin. 2019 May 8. doi: 10.3322/caac.21564. [Epub ahead of print]

3.

Minimizing the burden of cancer in the United States: Goals for a high-performing health care system.

Yabroff KR, Gansler T, Wender RC, Cullen KJ, Brawley OW.

CA Cancer J Clin. 2019 May;69(3):166-183. doi: 10.3322/caac.21556. Epub 2019 Feb 20.

4.

Co-targeting EGFR and IKKβ/NF-κB signalling pathways in head and neck squamous cell carcinoma: a potential novel therapy for head and neck squamous cell cancer.

Li Z, Liao J, Yang Z, Choi EY, Lapidus RG, Liu X, Cullen KJ, Dan H.

Br J Cancer. 2019 Feb;120(3):306-316. doi: 10.1038/s41416-018-0351-z. Epub 2018 Dec 26.

PMID:
30585254
5.

A comparison of two biological markers of recent hepatitis C virus (HCV) infection: implications for the monitoring of interventions and strategies to reduce HCV transmission among people who inject drugs.

Hope VD, Harris RJ, Vickerman P, Platt L, Shute J, Cullen KJ, Ijaz S, Mandal S, Ncube F, Desai M, Parry JV.

Euro Surveill. 2018 Nov;23(47). doi: 10.2807/1560-7917.ES.2018.23.47.1700635.

6.

Antitumor Activity of Nivolumab in Recurrent and Metastatic Nasopharyngeal Carcinoma: An International, Multicenter Study of the Mayo Clinic Phase 2 Consortium (NCI-9742).

Ma BBY, Lim WT, Goh BC, Hui EP, Lo KW, Pettinger A, Foster NR, Riess JW, Agulnik M, Chang AYC, Chopra A, Kish JA, Chung CH, Adkins DR, Cullen KJ, Gitlitz BJ, Lim DW, To KF, Chan KCA, Lo YMD, King AD, Erlichman C, Yin J, Costello BA, Chan ATC.

J Clin Oncol. 2018 May 10;36(14):1412-1418. doi: 10.1200/JCO.2017.77.0388. Epub 2018 Mar 27.

7.

Genotyping of high-risk anal human papillomavirus (HPV): ion torrent-next generation sequencing vs. linear array.

Nowak RG, Ambulos NP, Schumaker LM, Mathias TJ, White RA, Troyer J, Wells D, Charurat ME, Bentzen SM, Cullen KJ.

Virol J. 2017 Jun 13;14(1):112. doi: 10.1186/s12985-017-0771-z.

8.

Injection into the jugular vein among people who inject drugs in the United Kingdom: Prevalence, associated factors and harms.

Hope VD, Iversen J, Cullen KJ, Parry JV, Maher L, Nucbe F.

Int J Drug Policy. 2017 Aug;46:28-33. doi: 10.1016/j.drugpo.2017.05.005. Epub 2017 Jun 3.

PMID:
28586700
9.

Is the recent emergence of mephedrone injecting in the United Kingdom associated with elevated risk behaviours and blood borne virus infection?

Hope VD, Cullen KJ, Smith J, Jessop L, Parry J, Ncube F.

Euro Surveill. 2016 May 12;21(19). doi: 10.2807/1560-7917.ES.2016.21.19.30225.

10.

Next-Generation Sequencing-Based HPV Genotyping Assay Validated in Formalin-Fixed, Paraffin-Embedded Oropharyngeal and Cervical Cancer Specimens.

Ambulos NP Jr, Schumaker LM, Mathias TJ, White R, Troyer J, Wells D, Cullen KJ.

J Biomol Tech. 2016 Jul;27(2):46-52. doi: 10.7171/jbt.16-2702-004. Epub 2016 Mar 7.

11.

A positive feedback loop involving EGFR/Akt/mTORC1 and IKK/NF-kB regulates head and neck squamous cell carcinoma proliferation.

Li Z, Yang Z, Passaniti A, Lapidus RG, Liu X, Cullen KJ, Dan HC.

Oncotarget. 2016 May 31;7(22):31892-906. doi: 10.18632/oncotarget.7441.

12.

IKK phosphorylation of NF-κB at serine 536 contributes to acquired cisplatin resistance in head and neck squamous cell cancer.

Li Z, Yang Z, Lapidus RG, Liu X, Cullen KJ, Dan HC.

Am J Cancer Res. 2015 Sep 15;5(10):3098-110. eCollection 2015.

13.

Phase II trial of dasatinib for recurrent or metastatic c-KIT expressing adenoid cystic carcinoma and for nonadenoid cystic malignant salivary tumors.

Wong SJ, Karrison T, Hayes DN, Kies MS, Cullen KJ, Tanvetyanon T, Argiris A, Takebe N, Lim D, Saba NF, Worden FP, Gilbert J, Lenz HJ, Razak AR, Roberts JD, Vokes EE, Cohen EE.

Ann Oncol. 2016 Feb;27(2):318-23. doi: 10.1093/annonc/mdv537. Epub 2015 Nov 23.

14.

Risk of HIV and Hepatitis B and C Over Time Among Men Who Inject Image and Performance Enhancing Drugs in England and Wales: Results From Cross-Sectional Prevalence Surveys, 1992-2013.

Hope VD, Harris R, McVeigh J, Cullen KJ, Smith J, Parry JV, DeAngelis D, Ncube F.

J Acquir Immune Defic Syndr. 2016 Mar 1;71(3):331-7. doi: 10.1097/QAI.0000000000000835.

15.

Correlation of p16 expression and HPV type with survival in oropharyngeal squamous cell cancer.

Liu SZ, Zandberg DP, Schumaker LM, Papadimitriou JC, Cullen KJ.

Oral Oncol. 2015 Sep;51(9):862-9. doi: 10.1016/j.oraloncology.2015.06.014. Epub 2015 Jul 13.

PMID:
26183400
16.

Going into the groin: Injection into the femoral vein among people who inject drugs in three urban areas of England.

Hope VD, Scott J, Cullen KJ, Parry JV, Ncube F, Hickman M.

Drug Alcohol Depend. 2015 Jul 1;152:239-45. doi: 10.1016/j.drugalcdep.2015.03.029. Epub 2015 Apr 9.

PMID:
25913887
17.

Hepatitis B vaccination for people who inject drugs.

Hope VD, Mandal S, Cullen KJ, Balogun K, Ncube F.

Lancet. 2015 Jan 10;385(9963):115-6. doi: 10.1016/S0140-6736(15)60020-4. No abstract available.

PMID:
25706467
18.

A phase I dose escalation trial of MAGE-A3- and HPV16-specific peptide immunomodulatory vaccines in patients with recurrent/metastatic (RM) squamous cell carcinoma of the head and neck (SCCHN).

Zandberg DP, Rollins S, Goloubeva O, Morales RE, Tan M, Taylor R, Wolf JS, Schumaker LM, Cullen KJ, Zimrin A, Ord R, Lubek JE, Suntharalingam M, Papadimitriou JC, Mann D, Strome SE, Edelman MJ.

Cancer Immunol Immunother. 2015 Mar;64(3):367-79. doi: 10.1007/s00262-014-1640-x. Epub 2014 Dec 24.

19.

Oropharyngeal cancer as a driver of racial outcome disparities in squamous cell carcinoma of the head and neck: 10-year experience at the University of Maryland Greenebaum Cancer Center.

Zandberg DP, Liu S, Goloubeva O, Ord R, Strome SE, Suntharalingam M, Taylor R, Morales RE, Wolf JS, Zimrin A, Lubek JE, Schumaker LM, Cullen KJ.

Head Neck. 2016 Apr;38(4):564-72. doi: 10.1002/hed.23933. Epub 2015 Jun 30.

20.

Sex work amongst people who inject drugs in England, Wales and Northern Ireland: findings from a National Survey of Health Harms and Behaviours.

Croxford S, Platt L, Hope VD, Cullen KJ, Parry JV, Ncube F.

Int J Drug Policy. 2015 Apr;26(4):429-33. doi: 10.1016/j.drugpo.2014.09.014. Epub 2014 Oct 5. No abstract available.

PMID:
25449053
21.

Factors associated with recently acquired hepatitis C virus infection in people who inject drugs in England, Wales and Northern Ireland: new findings from an unlinked anonymous monitoring survey.

Cullen KJ, Hope VD, Croxford S, Shute J, Ncube F, Parry JV.

Epidemiol Infect. 2015 May;143(7):1398-407. doi: 10.1017/S0950268814002040. Epub 2014 Aug 14.

PMID:
25119383
22.

Hepatitis C virus infection epidemiology among people who inject drugs in Europe: a systematic review of data for scaling up treatment and prevention.

Wiessing L, Ferri M, Grady B, Kantzanou M, Sperle I, Cullen KJ; EMCDDA DRID group, Hatzakis A, Prins M, Vickerman P, Lazarus JV, Hope VD, Matheï C.

PLoS One. 2014 Jul 28;9(7):e103345. doi: 10.1371/journal.pone.0103345. eCollection 2014. Review.

23.

Emergence of HPV16-positive oropharyngeal cancer in Black patients over time: University of Maryland 1992-2007.

Zandberg DP, Liu S, Goloubeva OG, Schumaker LM, Cullen KJ.

Cancer Prev Res (Phila). 2015 Jan;8(1):12-9. doi: 10.1158/1940-6207.CAPR-14-0089-T. Epub 2014 Jun 10.

24.

Factors associated with the use of cleaned needles and syringes among people who inject drugs in the UK: who should we target to minimise the risks?

Hope VD, Cullen KJ, Croxford S, Parry JV, Ncube F.

Int J Drug Policy. 2014 Sep;25(5):924-7. doi: 10.1016/j.drugpo.2014.02.008. Epub 2014 Feb 28. No abstract available.

PMID:
24835441
25.

The role of human papillomavirus in nongenital cancers.

Zandberg DP, Bhargava R, Badin S, Cullen KJ.

CA Cancer J Clin. 2013 Jan;63(1):57-81. doi: 10.3322/caac.21167. Epub 2012 Dec 19. Review.

26.

Role of neurofilament light polypeptide in head and neck cancer chemoresistance.

Chen B, Chen J, House MG, Cullen KJ, Nephew KP, Guo Z.

Mol Cancer Res. 2012 Mar;10(3):305-15. doi: 10.1158/1541-7786.MCR-11-0300. Epub 2012 Jan 13.

27.

Novel biomarker panel predicts prognosis in human papillomavirus-negative oropharyngeal cancer: an analysis of the TAX 324 trial.

Wu Y, Posner MR, Schumaker LM, Nikitakis N, Goloubeva O, Tan M, Lu C, Iqbal S, Lorch J, Sarlis NJ, Haddad RI, Cullen KJ.

Cancer. 2012 Apr 1;118(7):1811-7. doi: 10.1002/cncr.26485. Epub 2011 Aug 25.

28.

Impact of early percutaneous endoscopic gastrostomy tube placement on nutritional status and hospitalization in patients with head and neck cancer receiving definitive chemoradiation therapy.

Rutter CE, Yovino S, Taylor R, Wolf J, Cullen KJ, Ord R, Athas M, Zimrin A, Strome S, Suntharalingam M.

Head Neck. 2011 Oct;33(10):1441-7. doi: 10.1002/hed.21624. Epub 2010 Dec 15.

PMID:
21928416
29.

GPx3 promoter hypermethylation is a frequent event in human cancer and is associated with tumorigenesis and chemotherapy response.

Chen B, Rao X, House MG, Nephew KP, Cullen KJ, Guo Z.

Cancer Lett. 2011 Oct 1;309(1):37-45. doi: 10.1016/j.canlet.2011.05.013.

PMID:
21684681
30.

Phase II study evaluating the addition of cetuximab to the concurrent delivery of weekly carboplatin, paclitaxel, and daily radiotherapy for patients with locally advanced squamous cell carcinomas of the head and neck.

Suntharalingam M, Kwok Y, Goloubeva O, Parekh A, Taylor R, Wolf J, Zimrin A, Strome S, Ord R, Cullen KJ.

Int J Radiat Oncol Biol Phys. 2012 Apr 1;82(5):1845-50. doi: 10.1016/j.ijrobp.2011.02.062. Epub 2011 May 19.

31.

Survival and human papillomavirus in oropharynx cancer in TAX 324: a subset analysis from an international phase III trial.

Posner MR, Lorch JH, Goloubeva O, Tan M, Schumaker LM, Sarlis NJ, Haddad RI, Cullen KJ.

Ann Oncol. 2011 May;22(5):1071-7. doi: 10.1093/annonc/mdr006. Epub 2011 Feb 11.

32.

A novel soft-tissue in vitro model for bisphosphonate-associated osteonecrosis.

Scheper M, Chaisuparat R, Cullen K, Meiller T.

Fibrogenesis Tissue Repair. 2010 Apr 1;3:6. doi: 10.1186/1755-1536-3-6.

33.

beta-Tubulin-II expression strongly predicts outcome in patients receiving induction chemotherapy for locally advanced squamous carcinoma of the head and neck: a companion analysis of the TAX 324 trial.

Cullen KJ, Schumaker L, Nikitakis N, Goloubeva O, Tan M, Sarlis NJ, Haddad RI, Posner MR.

J Clin Oncol. 2009 Dec 20;27(36):6222-8. doi: 10.1200/JCO.2009.23.0953. Epub 2009 Nov 16.

PMID:
19917838
34.

A novel bioassay model to determine clinically significant bisphosphonate levels.

Scheper MA, Badros A, Salama AR, Warburton G, Cullen KJ, Weikel DS, Meiller TF.

Support Care Cancer. 2009 Dec;17(12):1553-7. doi: 10.1007/s00520-009-0710-7. Epub 2009 Aug 4.

PMID:
19653010
35.

Racial survival disparity in head and neck cancer results from low prevalence of human papillomavirus infection in black oropharyngeal cancer patients.

Settle K, Posner MR, Schumaker LM, Tan M, Suntharalingam M, Goloubeva O, Strome SE, Haddad RI, Patel SS, Cambell EV 3rd, Sarlis N, Lorch J, Cullen KJ.

Cancer Prev Res (Phila). 2009 Sep;2(9):776-81. doi: 10.1158/1940-6207.CAPR-09-0149. Epub 2009 Jul 29.

36.

Sequential therapy for the locally advanced larynx and hypopharynx cancer subgroup in TAX 324: survival, surgery, and organ preservation.

Posner MR, Norris CM, Wirth LJ, Shin DM, Cullen KJ, Winquist EW, Blajman CR, Mickiewicz EA, Frenette GP, Plinar LF, Cohen RB, Steinbrenner LM, Freue JM, Gorbunova VA, Tjulandin SA, Raez LE, Adkins DR, Tishler RB, Roessner MR, Haddad RI; TAX 324 Study Group.

Ann Oncol. 2009 May;20(5):921-7. doi: 10.1093/annonc/mdn752. Epub 2009 Jan 29.

PMID:
19179556
37.

Effect of zoledronic acid on oral fibroblasts and epithelial cells: a potential mechanism of bisphosphonate-associated osteonecrosis.

Scheper MA, Badros A, Chaisuparat R, Cullen KJ, Meiller TF.

Br J Haematol. 2009 Mar;144(5):667-76. doi: 10.1111/j.1365-2141.2008.07504.x. Epub 2008 Nov 20.

38.

Elevated expression of glutathione S-transferase pi and p53 confers poor prognosis in head and neck cancer patients treated with chemoradiotherapy but not radiotherapy alone.

Schumaker L, Nikitakis N, Goloubeva O, Tan M, Taylor R, Cullen KJ.

Clin Cancer Res. 2008 Sep 15;14(18):5877-83. doi: 10.1158/1078-0432.CCR-08-0998.

39.

Mitochondria as a critical target of the chemotheraputic agent cisplatin in head and neck cancer.

Cullen KJ, Yang Z, Schumaker L, Guo Z.

J Bioenerg Biomembr. 2007 Feb;39(1):43-50. Review.

PMID:
17318397
42.

Glutathione S-transferase pi amplification is associated with cisplatin resistance in head and neck squamous cell carcinoma cell lines and primary tumors.

Cullen KJ, Newkirk KA, Schumaker LM, Aldosari N, Rone JD, Haddad BR.

Cancer Res. 2003 Dec 1;63(23):8097-102.

43.

Capecitabine induces rapid, sustained response in two patients with extensive oral verrucous carcinoma.

Salesiotis A, Soong R, Diasio RB, Frost A, Cullen KJ.

Clin Cancer Res. 2003 Feb;9(2):580-5.

44.

Inhibition of glutathione synthesis reverses Bcl-2-mediated cisplatin resistance.

Rudin CM, Yang Z, Schumaker LM, VanderWeele DJ, Newkirk K, Egorin MJ, Zuhowski EG, Cullen KJ.

Cancer Res. 2003 Jan 15;63(2):312-8.

45.

Insulin-like growth factor II (IGF-II) immunohistochemistry in breast cancer: relationship with the most important morphological and biochemical prognostic parameters.

Giani C, Campani D, Rasmussen A, Fierabracci P, Miccoli P, Bevilacqua G, Pinchera A, Cullen KJ.

Int J Biol Markers. 2002 Apr-Jun;17(2):90-5.

PMID:
12113587
46.

A happy outcome to a bad problem.

Mankin HJ, Isaacson KB, Cullen KJ.

J Bone Joint Surg Am. 2002 Jul;84(7):1251-3. No abstract available.

PMID:
12107329
47.

MMP-2 and MMP-9 expression in breast cancer-derived human fibroblasts is differentially regulated by stromal-epithelial interactions.

Singer CF, Kronsteiner N, Marton E, Kubista M, Cullen KJ, Hirtenlehner K, Seifert M, Kubista E.

Breast Cancer Res Treat. 2002 Mar;72(1):69-77.

PMID:
12000221
48.

Planned neck dissection for advanced primary head and neck malignancy treated with organ preservation therapy: disease control and survival outcomes.

Newkirk KA, Cullen KJ, Harter KW, Picken CA, Sessions RB, Davidson BJ.

Head Neck. 2001 Feb;23(2):73-9.

PMID:
11303636
49.

Local feedback mechanisms in human breast cancer.

Singer CF, Kubista E, Garmroudi F, Cullen KJ.

Breast Cancer Res Treat. 2000 Sep;63(2):95-104. Review.

PMID:
11097086
50.

Decreased cisplatin/DNA adduct formation is associated with cisplatin resistance in human head and neck cancer cell lines.

Yang Z, Faustino PJ, Andrews PA, Monastra R, Rasmussen AA, Ellison CD, Cullen KJ.

Cancer Chemother Pharmacol. 2000;46(4):255-62.

PMID:
11052622

Supplemental Content

Loading ...
Support Center